Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00578448 · ClinicalTrials.gov registry record · Phase 2
Belatacept Pharmacokinetic Trial in Renal Transplantation
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
NCT00578448 is a Phase 2 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 14 participants.
The verdict
NCT00578448, a Phase 2 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the pharmacokinetics and safety of belatacept in de novo renal transplant subjects treated with belatacept-based immunosuppressant medication
Interventions
- DRUG Belatacept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2008-03 |
| Est. Completion | 2012-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00578448
The ClinicalTrials.gov registry entry for NCT00578448 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Belatacept is the first listed.
NCT00578448 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00578448 about?
NCT00578448 is a clinical study titled "Belatacept Pharmacokinetic Trial in Renal Transplantation". The purpose of this study is to assess the pharmacokinetics and safety of belatacept in de novo renal transplant subjects treated with belatacept-based immunosuppressant medication
What is the current status of trial NCT00578448?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2008-03. Estimated completion is 2012-09.
What interventions are being tested in trial NCT00578448?
The interventions under investigation include: Belatacept (DRUG).
Who is sponsoring clinical trial NCT00578448?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.